[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"kidney-injury-acute\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:kidney-injury-acute":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,39,63,92],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100595262","a-machine-learning-prediction-model-for-postoperative-acute-kidney-injury-in-non-cardiac-surgery-patients-100595262",false,"NCT07030166","A Machine Learning Prediction Model for Postoperative Acute Kidney Injury in Non-Cardiac Surgery Patients","A Machine Learning Prediction Model for Postoperative Acute Kidney Injury in Non-Cardiac Surgery Patients: Development, Validation, and the Incremental Value of Frailty Assessment","Inclusion Criteria:\n\n* 18 years old or above\n* Undergo non-cardiac surgery\n\nExclusion Criteria:\n\n* At least one measurement of serum creatinine (SCr) was not conducted before and after the operation\n* End-stage renal disease (ESRD) that has received dialysis within the past year\n* Baseline SCr ≥ 4.5 mg\u002Fdl (because the clinical criteria for AKI based on elevated SCr may not be applicable to these patients)\n* Acute kidney injury occurred within 7 days before the operation\n* The surgical procedure is renal surgery\n* The operation time is less than 2 hours","ALL","18 Years",{"count":19,"type":20},10000,"ESTIMATED","1 Year","OBSERVATIONAL","Primary objectives of this study is to develop and validate a predictive model for acute kidney injury after non-cardiac surgery based on machine learning. Secondary objectives of this study is to incorporate frailty assessment as a new predictor into the model and measure its incremental value was measured.",[25],"Kidney Injury, Acute","RECRUITING","2026-03-27",{"date":29,"type":30},"2026-04-02","ACTUAL",{"date":32,"type":30},"2025-07-01",{"date":34,"type":20},"2026-12-31",{"name":36,"class":37},"Lanyue Zhu","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":45,"targetDuration":4,"studyType":47,"phases":48,"briefSummary":50,"conditions":51,"keywords":52,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":38},"100594179","phase-2-inorganic-nitrate-nano3-prevention-of-contrast-associated-acute-kidney-injury-100594179","NCT07016074","Inorganic Nitrate (NaNO3) Prevention of Contrast-Associated Acute Kidney Injury","Inclusion Criteria:\n\n* Planned coronary angiogram or contrast-enhanced CT scan.\n* High-risk for contrast-associated acute kidney injury (AKI) with creatine\u002FGlomerular filtration rate (GFR) within 90 days as defined as:\n\n  1. Undergoing coronary angiogram with GFR \\\u003C45 mL\u002Fmin\u002F1.73m2 OR\n  2. Undergoing coronary angiogram with GFR \\\u003C60 mL\u002Fmin\u002F1.73m2 and concurrent risk of AKI as defined by Hamilton et al. BMC2 risk prediction model ≥ 7%.\n\n     OR\n  3. Undergoing contrast-enhanced CT scan with GFR\\\u003C45 mL\u002Fmin\u002F1.73m2\n* If subject is a woman of child-bearing potential, subject agrees to the use of highly effective contraception starting at screening and during study participation.\n* Ability to take oral medication and be willing to adhere to the study intervention regimen.\n* Ability to understand and willingness to agree to an informed consent\n\nExclusion Criteria:\n\n* Already fulfilling definition of acute kidney injury prior to contrast exposure by kidney disease improving global outcomes (KDIGO) criteria (absolute increase in creatinine from baseline of 0.3mg\u002FdL or more OR relative increase in creatine of 50% or more from baseline).\n* Primary indication for Percutaneous Coronary Intervention (PCI) including acute ST-segment elevation myocardial infarction\n* End-stage renal disease actively on dialysis.\n* Received any intravenous or intraarterial contrast within five days from planned contrast administration.\n* Cardiac arrest within 14 days of planned contrast administration.\n* Systolic blood pressure \\\u003C 100mmHg or diastolic blood pressure \\\u003C60mmHg OR currently receiving inotropes or vasopressors for hemodynamic support.\n* History of hypersensitivity or known allergy to any of the components of the investigational product or placebo including sodium nitrate, inorganic nitrate, beet root juice, or lactose. This does not include lactose intolerance.\n* Pregnancy or nursing female\n* Participation in other investigational trials within the past 30 days prior to enrollment.\n* Use of tadalafil within 48 hours, sildenafil or vardenafil within 24 hours, and avanafil within 12 hours of initiation of trial medication. If participant is on continuous dosing of tadalafil, sildenafil, vardenafil, or avanafil, they will be excluded from the trial. If participant is on intermittent dosing of tadalafil, sildenafil, vardenafil, or avanafil, patient agrees to withhold use of medication for duration of medication treatment extending 48 hours after the final dose.",{"count":46,"type":20},100,"INTERVENTIONAL",[49],"PHASE2","This pilot study is designed to test the logistics and recruitment of a trial testing the benefit of sodium nitrate in the prevention of contrast-associated kidney injury in a group of patients at high-risk.",[25],[53],"Sodium Nitrate","2026-02-22",{"date":56,"type":30},"2026-02-24",{"date":58,"type":30},"2025-06-30",{"date":60,"type":20},"2026-07",{"name":62,"class":37},"University of Michigan",{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":67,"acronym":4,"eligibilityCriteria":68,"healthyVolunteers":69,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":70,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":72,"conditions":73,"keywords":75,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":4},"100612245","clinical-performance-of-a-point-of-care-creatinine-testing-system-in-individuals-with-kidney-disease-100612245","NCT07251075","Clinical Performance of a Point-of-Care Creatinine Testing System in Individuals With Kidney Disease","Inclusion Criteria:\n\n* Abnormal creatinine levels or suspected kidney disease;\n* Aged 18 and above, gender is not limited;\n* Voluntarily participate in this clinical study by signing the informed consent form.\n\nExclusion Criteria:\n\n* The HCT range is not within 25-65%;\n* Severe mental illness or other conditions that make the patient unable to cooperate;\n* Inability to read or write in English language;\n* Incomplete subject information (including but not limited to gender, age, education level, clinical diagnosis information; etc.);\n* Previous experience with this creatinine monitoring system or similar self-monitoring devices (including but not limited to those for glucose, ketones, total cholesterol, etc.);\n* Other conditions that, in the opinion of the investigator, make participation in this clinical trial inappropriate.",true,{"count":71,"type":20},200,"The goal of this clinical performance study is to evaluate the accuracy and usability of the Eaglenos Creatinine Test System（referred to as EG）, a point-of-care testing (POCT) system that consists of a handheld device and its associated creatinine test strips, intended for home use by laypersons with non-dialysis-dependent kidney disease.\n\nThe main questions it aims to answer are:\n\n1. How consistent are creatinine measurements from the investigational creatinine test system compared with the clinical standard method?\n2. How usable is the Creatinine Monitoring System for laypersons in a home setting?\n\nResearchers will compare creatinine results obtained with the investigational creatinine test system (fingerstick capillary whole blood) to those from a Cobas biochemical analysis system（referred to as Cobas) (venous plasma) to determine whether the investigational device provides accurate and reliable measurements.\n\nParticipants will:\n\n1. Provide a venous blood sample for comparative testing.\n2. Perform self-testing using the Creatinine Monitoring System without prior training.\n3. Complete a usability questionnaire about their experience with the investigational creatinine test system.",[74,25],"Chronic Kidney Diseases",[76,77,78,79,80],"Creatinine","Chronic kidney diseases","Kidney Injury, acute","POCT","Eaglenos","NOT_YET_RECRUITING","2025-11-18",{"date":84,"type":30},"2025-11-26",{"date":86,"type":20},"2025-11-30",{"date":88,"type":20},"2025-12-30",{"name":90,"class":91},"Tingting Xu","INDUSTRY",{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":99,"enrollmentInfo":100,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":102,"conditions":103,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":38},"100453801","cardiopulmonary-bypass-induced-red-blood-cell-lysis-100453801","NCT05189262","Cardiopulmonary Bypass Induced Red Blood Cell Lysis","Extra-Cellular Hemoglobin, Organ Injury in Extended Cardiopulmonary Bypass","Inclusion Criteria:\n\n* Admitted to UMMC for cardiac procedure\n* Age: \\>\u002F=18 y.o TO 88 y.o.\n* Undergoing CPB \\>1hr for the following surgeries (a) complex cardiac surgery (b) heart valve replacement surgery OR (c) CABG surgery.\n\nExclusion Criteria:\n\n* Pregnant\n* Non English speaking\n* Unable to consent or have Legally Authorized Representative (LAR) assent to study","88 Years",{"count":101,"type":20},150,"Studying the dynamics of red blood cell lysis, pfH, protective proteins and organ injury, limits will be set for safe levels of pfH following the use of CPB. These results will be compared to existing laboratory-based methods for determining red blood cell damage to predict CPB assist device safety. Further, results from the studies described in this proposal will help develop therapeutic strategies to benefit patients by early detection of pfH and clearance protein levels that occur during CPB.",[104,105,25],"Cardiopulmonary Bypass","Cardiac Surgery","2025-08-13",{"date":108,"type":30},"2025-08-19",{"date":110,"type":30},"2022-03-22",{"date":112,"type":20},"2027-12-01",{"name":114,"class":37},"University of Maryland, Baltimore"]